[目的]探讨西黄丸对三阴性乳腺癌肺转移的机制。[方法]构建三阴性乳腺癌4T1-BALB/c原位荷瘤小鼠,流式细胞术检测荷瘤小鼠血液、骨髓、肺组织内骨髓源性抑制细胞(MDSCs);通过苏木精-伊红(HE)染色确定小鼠肺转移微环境形成时间;利用蛋白...[目的]探讨西黄丸对三阴性乳腺癌肺转移的机制。[方法]构建三阴性乳腺癌4T1-BALB/c原位荷瘤小鼠,流式细胞术检测荷瘤小鼠血液、骨髓、肺组织内骨髓源性抑制细胞(MDSCs);通过苏木精-伊红(HE)染色确定小鼠肺转移微环境形成时间;利用蛋白质印迹(Western blotting)检测肺组织相关蛋白水平;通过对比各组小鼠肺转移微环境形成时间、肺组织骨髓及外周血中MDSCs数量、肺转移结节、肺转移组织相关蛋白探究西黄丸对乳腺癌肺转移的作用及机制。[结果]西黄丸及乳香、没药药对均在第14天对移植瘤有显著抑制作用;西黄丸能够延长乳腺癌肺转移出现时间(17 d vs. 14 d),且可以显著减少乳腺癌肺转移结节灶的数量;西黄丸能够抑制4T1-BALB/c荷瘤小鼠外周血及肺组织中MDSCs数量,且显著降低肺组织中基质金属蛋白酶9(MMP9)、S100A8/A9表达量。[结论]西黄丸可通过调控外周血及肺组织中MDSCs数量,抑制MMP9、S100A8/A9表达重塑乳腺癌肺转移微环境形成,达到抑制乳腺癌肺转移目的。研究为西黄丸临床抗肿瘤转移应用奠定基础。展开更多
Myeloid-derived suppressor cells(MDSCs)are a heterogeneous population of immature myeloid cells with immunosuppressive effects that are expanded under pathological conditions.In the past decade,MDSCs have generated si...Myeloid-derived suppressor cells(MDSCs)are a heterogeneous population of immature myeloid cells with immunosuppressive effects that are expanded under pathological conditions.In the past decade,MDSCs have generated significant research interest and increased attention.Recently,clinical observations and animal model studies have shown that MDSCs accumulate during the development of various autoimmune diseases,including primary Sjogren's syndrome(psS).psS is a common systemic autoimmune disease characterized by lymphocyte infiltration and tissue inflammation in the salivary glands(SG)and lacrimal glands,resulting in dry mouth and dry eyes.Here,we review the latest evidence and provide new insights into the roles of MDSCs in the pathogenesis of autoimmune diseases,focusing on the functional changes in MDSCs and their therapeutic potential in autoimmune diseases.展开更多
Successful human pregnancy requires the maternal immune system to recognize and tolerate the semi-allogeneic fetus. Myeloid-derived suppressor cells （MDSCs）, which are capable of inhibiting T-cell responses, are hig...Successful human pregnancy requires the maternal immune system to recognize and tolerate the semi-allogeneic fetus. Myeloid-derived suppressor cells （MDSCs）, which are capable of inhibiting T-cell responses, are highly increased in the early stages of pregnancy. Although recent reports indicate a role for MDSCs in fetal-maternal tolerance, little is known about the expansion of MDSCs during pregnancy. In the present study, we demonstrated that the trophoblast cell line HTR8/SVneo could instruct peripheral CD14＋ myelomonocytic cells toward a novel subpopulation of MDSCs, denoted as CD 14 ＋ H LA-DR-/=~w cells, with suppressive activity and increased expression of I DO 1, ARG- 1, a nd COX2. After interaction with HTR8/SVneo cells, CD14＋ myelomonocytic cells secrete high levels of CCL2, promoting the expression of signal transducer and activator of transcription 3. We utilized a neutralizing monoclonal antibody to reveal the prominent role of CCL2 in the induction of CD14＋HLA-DR-/low MDSCs. In combination, the results of the present study support a novel role for the cross-talk between the trophoblast cell line HTR8/SVneo and maternal CD14＋ myelomonocytic cells in initiating MDSCs induction, prompting a tolerogenic immune response to ensure a successful pregnancy.展开更多
文摘[目的]探讨西黄丸对三阴性乳腺癌肺转移的机制。[方法]构建三阴性乳腺癌4T1-BALB/c原位荷瘤小鼠,流式细胞术检测荷瘤小鼠血液、骨髓、肺组织内骨髓源性抑制细胞(MDSCs);通过苏木精-伊红(HE)染色确定小鼠肺转移微环境形成时间;利用蛋白质印迹(Western blotting)检测肺组织相关蛋白水平;通过对比各组小鼠肺转移微环境形成时间、肺组织骨髓及外周血中MDSCs数量、肺转移结节、肺转移组织相关蛋白探究西黄丸对乳腺癌肺转移的作用及机制。[结果]西黄丸及乳香、没药药对均在第14天对移植瘤有显著抑制作用;西黄丸能够延长乳腺癌肺转移出现时间(17 d vs. 14 d),且可以显著减少乳腺癌肺转移结节灶的数量;西黄丸能够抑制4T1-BALB/c荷瘤小鼠外周血及肺组织中MDSCs数量,且显著降低肺组织中基质金属蛋白酶9(MMP9)、S100A8/A9表达量。[结论]西黄丸可通过调控外周血及肺组织中MDSCs数量,抑制MMP9、S100A8/A9表达重塑乳腺癌肺转移微环境形成,达到抑制乳腺癌肺转移目的。研究为西黄丸临床抗肿瘤转移应用奠定基础。
文摘目的探讨膀胱癌MB49细胞来源的外泌体(exosomes)对MDSCs细胞扩增、活化的影响及机制。方法用超滤联合蔗糖重水密度梯度离心法分离纯化膀胱癌MB49细胞分泌的exosomes;电镜形态学分析及Western blotting鉴定;流式细胞仪检测MDSCs比例;ELISA检测VEGF和IL-6;RT-PCR和Western blotting检测cyclin D1、Arg-1 m RNA和蛋白的表达;Western blotting检测p-STAT3和p-NF-κB的变化。结果成功分离纯化得到膀胱癌MB49细胞分泌的exosomes。exosomes可促进MDSCs扩增及活化。实验组MDSCs比例明显升高;Cyclin D1及Arg-1 m RNA和蛋白的表达均上调;p-STAT3和p-NF-κB的表达也上调。结论膀胱癌MB49细胞来源的exosomes能促使MDSCs细胞扩增、活化。研究和分析MDSCs的免疫抑制机制,为疾病的治疗寻找行之有效的新靶点。
基金the National Natural Science Foundation of China(Grant Nos.82271854,81971542,82171771,91842304,and 82071817)the Shenzhen Science and Technology Program(JCYJ20210324114602008)+1 种基金the Hong Kong Research Grants Council Theme-Based Research Scheme(T12-703/19 R)the Centre for Oncology and Immunology under the Health@lnnoHK Initiative by the Innovation and Technology Commission,Hong Kong,China.
文摘Myeloid-derived suppressor cells(MDSCs)are a heterogeneous population of immature myeloid cells with immunosuppressive effects that are expanded under pathological conditions.In the past decade,MDSCs have generated significant research interest and increased attention.Recently,clinical observations and animal model studies have shown that MDSCs accumulate during the development of various autoimmune diseases,including primary Sjogren's syndrome(psS).psS is a common systemic autoimmune disease characterized by lymphocyte infiltration and tissue inflammation in the salivary glands(SG)and lacrimal glands,resulting in dry mouth and dry eyes.Here,we review the latest evidence and provide new insights into the roles of MDSCs in the pathogenesis of autoimmune diseases,focusing on the functional changes in MDSCs and their therapeutic potential in autoimmune diseases.
文摘Successful human pregnancy requires the maternal immune system to recognize and tolerate the semi-allogeneic fetus. Myeloid-derived suppressor cells （MDSCs）, which are capable of inhibiting T-cell responses, are highly increased in the early stages of pregnancy. Although recent reports indicate a role for MDSCs in fetal-maternal tolerance, little is known about the expansion of MDSCs during pregnancy. In the present study, we demonstrated that the trophoblast cell line HTR8/SVneo could instruct peripheral CD14＋ myelomonocytic cells toward a novel subpopulation of MDSCs, denoted as CD 14 ＋ H LA-DR-/=~w cells, with suppressive activity and increased expression of I DO 1, ARG- 1, a nd COX2. After interaction with HTR8/SVneo cells, CD14＋ myelomonocytic cells secrete high levels of CCL2, promoting the expression of signal transducer and activator of transcription 3. We utilized a neutralizing monoclonal antibody to reveal the prominent role of CCL2 in the induction of CD14＋HLA-DR-/low MDSCs. In combination, the results of the present study support a novel role for the cross-talk between the trophoblast cell line HTR8/SVneo and maternal CD14＋ myelomonocytic cells in initiating MDSCs induction, prompting a tolerogenic immune response to ensure a successful pregnancy.
